PAVmed Past Earnings Performance

Past criteria checks 0/6

PAVmed's earnings have been declining at an average annual rate of -39.6%, while the Medical Equipment industry saw earnings growing at 4.2% annually. Revenues have been growing at an average rate of 91.1% per year.

Key information

-39.6%

Earnings growth rate

0.6%

EPS growth rate

Medical Equipment Industry Growth4.3%
Revenue growth rate91.1%
Return on equity-344.4%
Net Margin-15,224.2%
Last Earnings Update30 Sep 2022

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown
Beta

How PAVmed makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

BST:1P5 Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 221-865726
30 Jun 221-725125
31 Mar 221-584322
31 Dec 211-513420
30 Sep 210-422617
30 Jun 210-352014
31 Mar 210-301512
31 Dec 200-351211
30 Sep 200-321110
30 Jun 200-30108
31 Mar 200-2898
31 Dec 190-1787
30 Sep 190-1776
30 Jun 190-1775
31 Mar 190-1975
31 Dec 180-1964
30 Sep 180-1263
30 Jun 180-1463
31 Mar 180-1053
31 Dec 170-1053
30 Sep 170-1253
30 Jun 170-953
31 Mar 170-952
31 Dec 160-642
30 Sep 160-541
30 Jun 160-331
31 Mar 160-221

Quality Earnings: 1P5 is currently unprofitable.

Growing Profit Margin: 1P5 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 1P5 is unprofitable, and losses have increased over the past 5 years at a rate of 39.6% per year.

Accelerating Growth: Unable to compare 1P5's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 1P5 is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (3.3%).


Return on Equity

High ROE: 1P5 has a negative Return on Equity (-344.39%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.